
Helus Pharma posts $103.1 million quarterly loss
Key points
- Helus Pharma (NASDAQ:HELP) reported a fiscal second-quarter 2027 net loss of $103.1 million, compared with $33.7 million a year earlier.
- Cash reached $171.1 million, while operating cash outflows totalled $35.3 million, compared with $34.5 million in the prior-year quarter.
- The company completed enrollment of 223 participants in its Phase 3 APPROACH trial, with topline results expected in Q4 2026, while advancing HLP004 and HLP005.
Helus Pharma (NASDAQ:HELP) reported a fiscal second-quarter 2027 net loss of $103.1 million, compared with $33.7 million a year earlier.
Operating expenses increased to $104.5 million from $28.9 million, largely reflecting higher share-based compensation, while cash stood at $171.1 million at September 30.
"We continue to expect topline results from the APPROACH study in the fourth quarter of 2026, and we remain focused on disciplined execution across our portfolio," said Helus Pharma Chief Executive Officer Michael Halstead.
Share-based compensation reached $65 million, compared with $377,000 a year earlier, while operating expenses excluding this non-cash charge increased to $39.6 million from $28.5 million.
Helus completed enrollment of 223 adults in its Phase 3 APPROACH study for major depressive disorder, while EMBRACE enrollment continues and participants move into the EXTEND extension study.
The company expects to begin its HLP004 Phase 2 generalized anxiety disorder study in the first quarter of 2027, advance an HLP005 development candidate in the second half of 2027, and has appointed Michael Halstead CEO, Suresh Durgam to its board and Mark Lawson independent chair.



